FGFR2 and infantile convulsions and choreoathetosis: FOENIX-CCA2, an open-label, multicentre phase II registrational trial in patients with iCCA harbouring FGFR2 gene fusions or other rearrangements (NCT02052778), was conducted based on FOENIX-1 results.